01—Abstract
Summary
Summary of the 10-K filed February 27, 2009. Cited figures are marked; the original filing is the authoritative source.
Gilead Sciences, Inc.'s 2008 annual report (10-K) highlights a year of significant growth, with total revenues reaching $5.34 billiona, a 36% increase from 2007.
This growth was primarily driven by strong performance in antiviral products, particularly Truvada and Atripla, which collectively generated $4.67 billionb in sales. The company also saw substantial growth in its Letairis product for pulmonary arterial hypertension. Gilead's strong financial position is underscored by its increasing cash reserves and a substantial stock repurchase program.
The company continues to invest heavily in research and development, with R&D expenses rising to $721.8 millionc, reflecting its commitment to expanding its pipeline of innovative therapeutics. Despite the robust financial performance, Gilead faces ongoing risks and challenges. The company's heavy reliance on its HIV product portfolio makes it vulnerable to shifts in treatment paradigms and increased competition, including potential generic challenges.
Furthermore, reliance on a few major wholesale distributors for U.S. sales, inventory management complexities, and the potential impact of international currency fluctuations present operational risks. The company is also navigating regulatory hurdles, as demonstrated by the FDA's request for an additional clinical study for aztreonam for inhalation solution. Gilead's proactive approach to managing these risks, including strategic collaborations and a focus on pipeline development, positions it for continued engagement in addressing unmet medical needs.
02—Key points
Key Highlights
- Total revenues grew by 36% to $5.34 billion in 2008, driven by strong antiviral product sales.
- Antiviral product sales, led by Truvada and Atripla, increased by 36% to $4.67 billion.
- Letairis sales showed substantial growth of 437% in 2008 due to its recent launch.
- Research and Development (R&D) expenses increased by 22% to $721.8 million, indicating continued investment in pipeline development.
- The company ended 2008 with $3.24 billion in cash, cash equivalents, and marketable securities, reflecting a strong liquidity position.
- Gilead repurchased approximately $1.97 billion of its common stock under its $3.00 billion stock repurchase program in 2008.
- The company faces significant competition in its key therapeutic areas, particularly HIV and Hepatitis B.
03—One dollar
Follow one dollar
Of each $1.00 of revenue in FY2008, Gilead Sciences, Inc. kept $0.37.
- Revenue$5.34B100.0%
- Cost of revenue−$1.13B21.1%
- Gross profit$4.21B78.9%
- Operating costs−$1.53B28.7%
- Operating income$2.68B50.2%
- Interest, other & tax−$699.6M13.1%
- Net income$1.98B37.1%
Where FY2008 revenue went
$5.34B- Net income: $1.98B, 37% of revenue
- Cost of revenue: $1.13B, 21% of revenue
- SG&A: $797.3M, 15% of revenue
- Other operating costs: $732.6M, 14% of revenue
- Interest, other & tax: $699.6M, 13% of revenue
Kept 37% as net income
Full revenue history →04—Financials
Financial Highlights
Figures from 10-KFY2008filed February 27, 2009Financial Statements
FY2008 against FY2007
| Line item | FY2008FY2007 | Change |
|---|---|---|
| Revenue | $5.34B$4.23B | +26.1% |
| Cost of Revenue | $1.13B$768.77M | +46.6% |
| Gross Profit | $4.21B$3.46B | +21.6% |
| SG&A Expenses | $797.34M$705.74M | +13.0% |
| Operating Expenses | $2.66B$2.07B | +28.6% |
| Operating Income | $2.68B$2.16B | +23.7% |
| Interest Expense | $65.24M$63.18M | +3.3% |
| Net Income | $1.98B$1.58B | +24.9% |
| EPS (Basic) | $1.07$0.85 | +25.7% |
| EPS (Diluted) | $1.03$0.82 | +25.6% |
| Shares Outstanding (Basic) | 1.84B1.86B | −0.9% |
| Shares Outstanding (Diluted) | 1.92B1.93B | −0.6% |
05—Questions
Frequently Asked Questions
What were Gilead Sciences' primary drivers of revenue growth in 2008?
Gilead Sciences' revenue growth in 2008 was primarily driven by its antiviral products, notably Truvada and Atripla, which saw significant sales increases. The company also experienced substantial growth in Letairis, a treatment for pulmonary arterial hypertension, and saw increases in AmBisome sales.
What are the main risks highlighted in the 10-K filing that could affect Gilead's future performance?
Key risks include a substantial portion of revenue being derived from HIV products, making the company vulnerable to changes in treatment paradigms or increased competition. Reliance on a few major U.S. wholesalers, inventory fluctuations, currency exchange rate volatility, and potential patent challenges are also significant concerns. Additionally, regulatory hurdles, such as the FDA's feedback on aztreonam for inhalation solution, pose risks to product commercialization.
How is Gilead managing its research and development pipeline and what are the key areas of focus?
Gilead Sciences is heavily investing in its R&D pipeline, with expenses increasing to $721.8 million in 2008. Key areas of focus include HIV therapeutics (with advancements in elvitegravir, GS 9350, and a fixed-dose regimen), Hepatitis C treatments (GS 9190 and GS 9450), cardiovascular treatments (daruSentan for hypertension and cicletanine for PAH), and respiratory treatments (aztreonam for inhalation solution). The company utilizes both internal development and strategic in-licensing and acquisitions to strengthen its pipeline.
What is Gilead's financial health and capital allocation strategy as of the end of 2008?
Gilead Sciences demonstrated strong financial health at the end of 2008, with $3.24 billion in cash, cash equivalents, and marketable securities, and growing working capital. The company actively returned value to shareholders through a $3.00 billion stock repurchase program, repurchasing approximately $1.97 billion of its common stock during 2008. Gilead continues to prioritize R&D investment to fuel future growth.
06—Continue